Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named CEO of the Year by The CEO Magazine, selected from 586 applicants in their 2025 Executive of the Year Awards program.

Under Maetzold's leadership, Castle has evolved from a startup into a leading diagnostics company with nearly 800 employees. The company has developed proprietary tests for skin cancers, Barrett's esophagus, and uveal melanoma. Castle has also earned recognition as a Top Workplace USA for four consecutive years, reflecting its strong people-first culture and values-driven approach to corporate growth.

Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program

FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded the CEO of the Year by The CEO Magazine. The Executive of the Year Awards program recognizes senior executives driving measurable impact, innovation and inspiration.

“This honor affirms what we at Castle have long known: Derek is a visionary leader whose ability to pair scientific innovation with a people-first approach has made a marked impact on patient care and our company,” said Frank Stokes, chief financial officer of Castle Biosciences. “His leadership has grown Castle from a startup into a leading diagnostics company, while fostering a culture that inspires and empowers nearly 800 employees. His unwavering commitment to improving patient outcomes and advancing the standard of care make him truly deserving of this recognition as CEO of the Year.”

Under Maetzold’s leadership, Castle has become a recognized innovator in the diagnostics field, with a portfolio of proprietary tests addressing critical challenges in skin cancers, Barrett’s esophagus and uveal melanoma. Beyond scientific and commercial success, Maetzold and the leadership team have cultivated a people-first culture, earning Castle four consecutive years of recognition as a Top Workplace USA, driven solely by employee feedback. His commitment to patients, innovation and culture has positioned Castle as both a leader in personalized medicine and a role model for values-driven corporate growth.

Earlier this year, Maetzold was named one of just 10 finalists selected from a pool of 586 applicants to the Executive of the Year Awards program. On Oct. 1, 2025, The CEO Magazine announced Maetzold as its CEO of the Year.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About the Executive of the Year Awards
The CEO Magazine’s Executive of the Year Awards is a prestigious program recognizing outstanding senior executives who drive success and make a meaningful impact across industries. Now in its second year in the United States, the awards celebrate leadership excellence with winners announced online.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06ba54e7-69f3-410b-a863-2ff1b4e6da4e

FAQ

Who is Derek Maetzold and what award did he receive in 2025?

Derek Maetzold is the founder, president and CEO of Castle Biosciences (CSTL), who was named CEO of the Year by The CEO Magazine in their 2025 Executive of the Year Awards program.

How many employees does Castle Biosciences (CSTL) currently have?

Castle Biosciences currently employs nearly 800 people under Derek Maetzold's leadership.

What types of diagnostic tests does Castle Biosciences (CSTL) develop?

Castle Biosciences develops proprietary diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma.

What workplace recognition has Castle Biosciences (CSTL) received?

Castle Biosciences has been recognized as a Top Workplace USA for four consecutive years, based on employee feedback.

How many applicants were considered for The CEO Magazine's 2025 Executive of the Year Awards?

The CEO Magazine's 2025 Executive of the Year Awards program had 586 applicants, from which Derek Maetzold was selected as CEO of the Year.